Systems biology for the clinician

Understanding stem cells to get abreast of breast cancer

Issues with reliability in HER2 testing and avastin for metastatic breast cancer

Targeting of breast cancer tumour initiating cells

Exemestane potential for hormone-receptor positive, early-stage breast cancer in the adjuvant setting

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

Neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

Combination therapy reduced HER2-positive breast cancers

CTCs predicted recurrence and death in patients with early-stage breast cancer

High CTC levels predicted poor outcome in metastatic breast cancer

Denosumab delayed first skeletal-related side effect

CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer